Osteoporosis in the European Union: a compendium of country-specific reports

[1]  R. Sund,et al.  Incidence of osteoporotic fractures in elderly women and men in Finland during 2005–2006: a population-based study , 2014, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.

[2]  J. Kanis,et al.  Incidence of Hip Fracture in Romania and the Development of a Romanian FRAX Model , 2013, Calcified Tissue International.

[3]  J. Kanis,et al.  Updated fracture incidence rates for the Italian version of FRAX® , 2013, Osteoporosis International.

[4]  U. Siebert,et al.  Economic burden of osteoporotic fractures in Austria , 2012, Health Economics Review.

[5]  M. Hiligsmann,et al.  Trends in hip fracture incidence and in the prescription of antiosteoporosis medications during the same time period in Belgium (2000–2007) , 2012, Arthritis care & research.

[6]  G. Lyritis,et al.  2011 guidelines for the diagnosis and treatment of osteoporosis in Greece. , 2012, Journal of musculoskeletal & neuronal interactions.

[7]  R. Negro,et al.  Healthcare Utilisation and Costs Associated with Adding Montelukast to Current Therapy in Patients with Mild to Moderate Asthma and Co-Morbid Allergic Rhinitis , 2012, PharmacoEconomics.

[8]  M. Hiligsmann,et al.  Hospitalisation costs of hip fractures in Belgium , 2011 .

[9]  O. Bruyère,et al.  Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club , 2011, Osteoporosis International.

[10]  T. Pieber,et al.  Epidemiology of hip fractures in Austria: evidence for a change in the secular trend , 2011, Osteoporosis International.

[11]  P. Pietschmann,et al.  [Austrian guidance for the pharmacologic treatment of osteoporosis in postmenopausal women: Addendum 2010]. , 2010, Wiener Medizinische Wochenschrift.

[12]  E. O'Shea,et al.  The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease , 2017 .

[13]  J. Reginster,et al.  Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club , 2010, Osteoporosis International.

[14]  P. Vestergaard,et al.  Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006 , 2010, Osteoporosis International.

[15]  K. Mulhall,et al.  Incidence of hip fracture in the Republic of Ireland and future projections: a population-based study , 2009, Osteoporosis International.

[16]  P. Pietschmann,et al.  [Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009]. , 2009, Wiener medizinische Wochenschrift. Supplement.

[17]  K. O’Rourke,et al.  Cost induced by hip fractures. , 2008, Irish medical journal.

[18]  H. Barros,et al.  Hip fractures cluster in space: an epidemiological analysis in Portugal , 2008, Osteoporosis International.

[19]  L. Melton,et al.  A reference standard for the description of osteoporosis. , 2008, Bone.

[20]  S. Sen,et al.  Cost-effectiveness of a fixed dose combination of alendronate and cholecalciferol in the treatment and prevention of osteoporosis in the United Kingdom and The Netherlands , 2008, Current medical research and opinion.

[21]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[22]  M. Péntek,et al.  Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003 , 2008, Osteoporosis International.

[23]  R. Sund.  Utilization of routinely collected administrative data in monitoring the incidence of aging dependent hip fracture , 2007 .

[24]  O. Johnell,et al.  Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial , 2007, Osteoporosis International.

[25]  A. Wertheimer,et al.  The burden-of-illness study on osteoporosis in the Slovenian female population , 2007, Pharmacy World & Science.

[26]  J. Díez,et al.  Epidemiology of fractures of the proximal femur associated with osteoporosis in Barcelona, Spain , 1989, Calcified Tissue International.

[27]  J. Lauridsen,et al.  Cost effectiveness of preventive home visits to the elderly , 2006, The European Journal of Health Economics.

[28]  Sergio L. Schmukler,et al.  Emerging Market Instability : Do Sovereign Ratings Affect Country Risk and Stock Returns ? , 1997 .

[29]  Saakje Mulder,et al.  Incidence and costs of injuries in The Netherlands. , 2006, European journal of public health.

[30]  J. Reginster,et al.  Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries , 2005, Rheumatology International.

[31]  G. Kobelt,et al.  Costs and quality of life of multiple sclerosis in Spain , 2006, The European Journal of Health Economics.

[32]  K. Kudrna,et al.  [Expense analysis of the proximal femoral fractures treatment]. , 2005, Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti.

[33]  S. Capri,et al.  Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events , 2005, Current medical research and opinion.

[34]  O. Johnell,et al.  The variable incidence of hip fracture in Southern Europe: The MEDOS study , 1994, Osteoporosis International.

[35]  J. Reginster,et al.  Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club , 2005, Osteoporosis International.

[36]  O. Johnell,et al.  Costs and quality of life associated with osteoporosis-related fractures in Sweden , 2005, Osteoporosis International.

[37]  J. Reginster,et al.  Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club , 2005, Osteoporosis International.

[38]  Peter Lüthje,et al.  Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients , 2003, Archives of Orthopaedic and Trauma Surgery.

[39]  O. Johnell,et al.  The components of excess mortality after hip fracture. , 2003, Bone.

[40]  D. Schwappach,et al.  Incidence and costs of osteoporosis-associated hip fractures in Austria. , 2001, Wiener klinische Wochenschrift.

[41]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.

[42]  J. Bentin,et al.  Costs Induced by Hip Fractures: A Prospective Controlled Study in Belgium , 2000, Osteoporosis International.

[43]  O. Johnell,et al.  Long-Term Risk of Osteoporotic Fracture in Malmö , 2000, Osteoporosis International.

[44]  G. Lyritis,et al.  Hip Fracture Epidemiology in Greece During 1977–1992 , 1998, Calcified Tissue International.

[45]  G. Mclauchlan,et al.  Epidemiology of fractures in 15,000 adults: the influence of age and gender. , 1998, The Journal of bone and joint surgery. British volume.

[46]  H. Wahner,et al.  Updated Data on Proximal Femur Bone Mineral Levels of US Adults , 1998, Osteoporosis International.

[47]  F. Fabris,et al.  Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy. , 1997, Maturitas.

[48]  M. Sosa,et al.  Epidemiology of proximal femoral fracture in Gran Canaria (Canary Islands). , 1993, Age and ageing.